|
As AI adoption accelerates across organisations in the Asia-Pacific region, applications teams are under pressure to deliver faster, more personalised, and more automated solutions while contending with rising delivery demands and constrained team capacity. Recent findings from Info-Tech Research Group show that many organisations risk falling short in 2026 due to mounting technical debt, constrained delivery capacity, and growing integration complexity. The firm's Applications Priorities 2026 report outlines four priorities to help applications leaders strengthen delivery fundamentals, scale AI responsibly, and realign execution with enterprise goals in the year ahead.
SYDNEY, March 25, 2026 /PRNewswire/ -- Applications teams across the APAC region continue to face a widening gap between AI ambition and delivery reality heading into 2026, according to recent findings from Info-Tech Research Group. As organisations accelerate AI initiatives, many are encountering delivery constraints and capability gaps that limit their ability to translate early momentum into sustained results. The global research and advisory firm's Applications Priorities 2026 report identifies the most critical execution gaps facing applications leaders and provides a structured set of priorities to help teams stabilise delivery, modernise practices, and support enterprise-wide AI adoption.
Info-Tech's report finds that while AI adoption is accelerating, most organisations still lack an up-to-date, enterprise-wide AI strategy, increasing execution risk for applications teams tasked with scaling delivery. At the same time, technical debt continues to constrain throughput and modernisation efforts, limiting organisations' ability to realise consistent value as AI becomes more deeply embedded in application delivery and operations. These challenges are particularly pronounced across APAC, where organisations are working to scale AI capabilities while addressing talent shortages and uneven delivery maturity.
"AI is accelerating faster than most applications practices are prepared for," says Andrew Kum-Seun, lead author of the report and research director at Info-Tech Research Group. "Organisations that focus only on pilots or tools will struggle to sustain results. Leaders who strengthen delivery fundamentals and deliberately integrate AI into roles, workflows, and architectures will be far better positioned to deliver consistent value."
Key Challenges Applications Leaders Face in 2026
Despite growing investment in AI-enabled development and automation, the Applications Priorities 2026 report shows that applications teams across APAC continue to face several structural challenges that constrain execution, especially as organisations work to scale delivery capacity and build the capabilities required to support AI-driven initiatives:
- Accumulating technical debt that slows throughput, increases costs, and limits modernisation
- Resource capacity constraints driven by skill shortages, growing backlogs, and unrealistic delivery expectations
- Integration complexity stemming from expanding SaaS, cloud, and third-party ecosystems
- Inconsistent governance and data practices that increase risk and limit AI reliability
These pressures are intensifying as applications teams are expected to support more personalised experiences, automate end-to-end processes, and operationalise AI across the delivery lifecycle.
Info-Tech's Four Applications Priorities for 2026
To help organisations navigate these challenges, Info-Tech's Applications Priorities 2026 report outlines the following four priorities designed to refocus applications teams on execution readiness and stakeholder value:
- Boost Solution Delivery With AI by embedding mature, proven AI capabilities into core delivery activities to improve throughput, quality, and predictability.
- Make AI a Team Member by rethinking team composition, capacity, and skills with AI acting as a collaborator rather than a standalone tool.
- Generate Contextual and Tailored Digital Experiences by delivering the right content, features, and workflows at the right time through data-informed design and AI-enabled personalisation.
- Enable End-to-End Business Process Automation by orchestrating deterministic and AI-driven automation across systems, workflows, and teams.
"Now is the time for applications practices to act," adds Kum-Seun. "Applications leaders need to reset priorities around the problems their stakeholders actually care about. When applications teams move in step with organisational ambition, AI becomes an accelerator instead of a source of risk."
The Applications Priorities 2026 report is grounded in real-world case examples, industry surveys, and Info-Tech diagnostic benchmarks. It provides practical guidance to help applications leaders reinforce delivery foundations, apply AI intentionally, and move from fragmented improvements to sustainable, enterprise-wide impact in the year ahead.
For exclusive and timely commentary from Info-Tech's experts, including Andrew Kum-Seun, and access to the complete Applications Priorities 2026 report, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is one of the world's leading and fastest-growing research and advisory firms, serving over 30,000 IT, HR, and marketing professionals around the globe. As a trusted product and service leader, the company delivers unbiased, highly relevant research and industry-leading advisory support to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide everything they need, from actionable tools to expert guidance, ensuring they deliver measurable results for their organisations.
To learn more about Info-Tech's HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm's SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
Photo - https://mma.prnasia.com/media2/2941592/Info_Tech_Research_Group_Applications_Priorities_2026__AI_Moment.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2941591/Info_Tech_Research_Group_Applications_Priorities_2026__AI_Moment.jpg?p=medium600
As AI adoption accelerates across organisations in the Asia-Pacific region, applications teams are under pressure to deliver faster, more personalised, and more automated solutions while contending with rising delivery demands and constrained team capacity. Recent findings from Info-Tech Research Group show that many organisations risk falling short in 2026 due to mounting technical debt, constrained delivery capacity, and growing integration complexity. The firm's Applications Priorities 2026 report outlines four priorities to help applications leaders strengthen delivery fundamentals, scale AI responsibly, and realign execution with enterprise goals in the year ahead.
SYDNEY, March 25, 2026 /PRNewswire/ -- Applications teams across the APAC region continue to face a widening gap between AI ambition and delivery reality heading into 2026, according to recent findings from Info-Tech Research Group. As organisations accelerate AI initiatives, many are encountering delivery constraints and capability gaps that limit their ability to translate early momentum into sustained results. The global research and advisory firm's Applications Priorities 2026 report identifies the most critical execution gaps facing applications leaders and provides a structured set of priorities to help teams stabilise delivery, modernise practices, and support enterprise-wide AI adoption.
Info-Tech's report finds that while AI adoption is accelerating, most organisations still lack an up-to-date, enterprise-wide AI strategy, increasing execution risk for applications teams tasked with scaling delivery. At the same time, technical debt continues to constrain throughput and modernisation efforts, limiting organisations' ability to realise consistent value as AI becomes more deeply embedded in application delivery and operations. These challenges are particularly pronounced across APAC, where organisations are working to scale AI capabilities while addressing talent shortages and uneven delivery maturity.
"AI is accelerating faster than most applications practices are prepared for," says Andrew Kum-Seun, lead author of the report and research director at Info-Tech Research Group. "Organisations that focus only on pilots or tools will struggle to sustain results. Leaders who strengthen delivery fundamentals and deliberately integrate AI into roles, workflows, and architectures will be far better positioned to deliver consistent value."
Key Challenges Applications Leaders Face in 2026
Despite growing investment in AI-enabled development and automation, the Applications Priorities 2026 report shows that applications teams across APAC continue to face several structural challenges that constrain execution, especially as organisations work to scale delivery capacity and build the capabilities required to support AI-driven initiatives:
- Accumulating technical debt that slows throughput, increases costs, and limits modernisation
- Resource capacity constraints driven by skill shortages, growing backlogs, and unrealistic delivery expectations
- Integration complexity stemming from expanding SaaS, cloud, and third-party ecosystems
- Inconsistent governance and data practices that increase risk and limit AI reliability
These pressures are intensifying as applications teams are expected to support more personalised experiences, automate end-to-end processes, and operationalise AI across the delivery lifecycle.
Info-Tech's Four Applications Priorities for 2026
To help organisations navigate these challenges, Info-Tech's Applications Priorities 2026 report outlines the following four priorities designed to refocus applications teams on execution readiness and stakeholder value:
- Boost Solution Delivery With AI by embedding mature, proven AI capabilities into core delivery activities to improve throughput, quality, and predictability.
- Make AI a Team Member by rethinking team composition, capacity, and skills with AI acting as a collaborator rather than a standalone tool.
- Generate Contextual and Tailored Digital Experiences by delivering the right content, features, and workflows at the right time through data-informed design and AI-enabled personalisation.
- Enable End-to-End Business Process Automation by orchestrating deterministic and AI-driven automation across systems, workflows, and teams.
"Now is the time for applications practices to act," adds Kum-Seun. "Applications leaders need to reset priorities around the problems their stakeholders actually care about. When applications teams move in step with organisational ambition, AI becomes an accelerator instead of a source of risk."
The Applications Priorities 2026 report is grounded in real-world case examples, industry surveys, and Info-Tech diagnostic benchmarks. It provides practical guidance to help applications leaders reinforce delivery foundations, apply AI intentionally, and move from fragmented improvements to sustainable, enterprise-wide impact in the year ahead.
For exclusive and timely commentary from Info-Tech's experts, including Andrew Kum-Seun, and access to the complete Applications Priorities 2026 report, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is one of the world's leading and fastest-growing research and advisory firms, serving over 30,000 IT, HR, and marketing professionals around the globe. As a trusted product and service leader, the company delivers unbiased, highly relevant research and industry-leading advisory support to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide everything they need, from actionable tools to expert guidance, ensuring they deliver measurable results for their organisations.
To learn more about Info-Tech's HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm's SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
Photo - https://mma.prnasia.com/media2/2941592/Info_Tech_Research_Group_Applications_Priorities_2026__AI_Moment.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2941591/Info_Tech_Research_Group_Applications_Priorities_2026__AI_Moment.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Applications Priorities 2026: AI Momentum Outpaces Application Delivery Readiness, Says Info-Tech Research Group
SHANGHAI, March 25, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatment of endometriosis. The dosing took place at the leading study site in China, Peking Union Medical College Hospital. This Phase III trial is a multicenter, randomized, double-blind, placebo-controlled study designed to confirm the safety and efficacy of HMI-115 in treating moderate-to-severe pain associated with endometriosis, with a treatment period of 24 weeks. HMI-115 is currently the first and only non-hormonal therapy globally to have entered Phase III clinical development.
Previously, HMI-115 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pain associated with endometriosis. Additionally, HMI-115 was granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). These recognitions from global regulatory authorities were primarily based on the results from a previously completed global multicenter Phase II clinical trial for HMI-115 in endometriosis, which demonstrated that HMI-115 achieved statistically significant improvement in moderate-to-severe pain associated with endometriosis, with no significant impact on key female hormones and no menopausal side effects. These findings have been published in The Lancet Obstetrics, Gynaecology, & Women's Health. Furthermore, Hope Medicine was nominated as "Best Startup" for the prestigious Prix Galien Award.
Regarding this significant clinical milestone, Professor Xiao Ruiping, Founder of Hope Medicine, stated:
"The initiation of the Phase III clinical trial for HMI-115 in endometriosis, marks a milestone achievement in our clinical development. Peking Union Medical College Hospital, as the leading site, is at the forefront of this Phase III study. Hope Medicine remains unwavering in its original commitment to bringing truly differentiated first-in-class medicines to patients worldwide."
Mr. Chen Xi, Chief Executive Officer of Hope Medicine, also commented:
"The launch of the Phase III trial signifies that the global development of HMI-115 for endometriosis has entered its final stage. Women's health is a key focus area for Hope Medicine, and we will drive this trial with the best speed and quality to bring this innovative treatment to patients as soon as possible."
About Endometriosis
Endometriosis is a common gynecological disease characterized by the implantation of endometrial cells outside the uterine cavity, typically presenting as a chronic inflammatory response. The endometrium is the mucosal tissue lining the uterine cavity, which undergoes hormone-dependent changes during the menstrual cycle. Endometriosis is common in women of reproductive age, with symptoms including lower abdominal and pelvic pain, dysmenorrhea, painful intercourse, and infertility. Comprehensive literature reports indicate that approximately 10% of women of reproductive age globally are affected by endometriosis, about 190 million women worldwide; 20%-50% of women with infertility have endometriosis, and 71%-87% of women with chronic pelvic pain have endometriosis. Endometriosis is one of the leading causes of dysmenorrhea, infertility, and chronic pelvic pain. The disease often leads to decreased quality of life, affecting patients' sexual health, psychological well-being, and social behavior. Globally, the disease represents a potential market size of approximately US$200 billion (according to McKinsey report), with significant unmet medical needs.
About Hope Medicine
Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research laboratories and offices in Beijing, Shanghai, and Nanjing, China. HopeMed is established on the in-depth expertise in translational medicine and decades of research of Professor Rui-Ping Xiao's laboratory at the Institute of Molecular Medicine of Peking University. Based on excellent scientific research and to improve the quality of life, HopeMed is committed to the research, development, and commercialization of first-in-class medicines for common and major diseases that threaten human health.
Forward-Looking Statements
This press release contains forward-looking statements that are primarily based on the current outlook, expectations, estimates, and projections of the company's management team. When using "anticipate," "believe," "may," "design," "effect," "assess," "expect," "predict," "target," "aim," "purpose" and any other similar words and expressions, in references to the company, the intention of the statement is forward-looking. Forward-looking statements are not guarantee of future performance and subject to risks and uncertainties, many of which are difficult to predict and often beyond the company's control, which could cause actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; changes in applicable laws or regulations. The company undertakes no public announcement obligation to update or revise any forward-looking statement in this press release, or to publicly announce any such updates or revisions, to reflect changes in our expectations or any events, circumstances or assumptions that affect these statements.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis
